Cancer name Lymphoma
Cancer Type DLBC
Immunotherapy type Adoptive Cell Therapy
Treatment polyfunctional CD4+ T cells
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Protein
Signature FoxP3
Official Symbol FOXP3
Mode of action PROT_D_DOWN
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Of note, the transferred polyfunctional CD4+T cells retained the polyfunctional phenotype through out the experimental timeframe, as reflected by their ability to concurrently produce IFNγ, IL-2 and TNFα, and by their reduced expressions of PD-1 and Foxp3.
PMID 27471650
Title IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells